GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (NAS:NOTV) » Definitions » Piotroski F-Score

Inotiv (Inotiv) Piotroski F-Score : 6 (As of Apr. 26, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Inotiv Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Inotiv has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Inotiv's Piotroski F-Score or its related term are showing as below:

NOTV' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 9
Current: 6

During the past 13 years, the highest Piotroski F-Score of Inotiv was 9. The lowest was 3. And the median was 4.


Inotiv Piotroski F-Score Historical Data

The historical data trend for Inotiv's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Piotroski F-Score Chart

Inotiv Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 4.00 6.00 3.00 6.00

Inotiv Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 3.00 5.00 6.00 6.00

Competitive Comparison of Inotiv's Piotroski F-Score

For the Diagnostics & Research subindustry, Inotiv's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inotiv's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Inotiv's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -9.994 + 1.84 + -9.663 + -15.388 = $-33.2 Mil.
Cash Flow from Operations was 12.836 + 3.694 + 18.763 + -6.545 = $28.7 Mil.
Revenue was 151.463 + 157.468 + 140.74 + 135.501 = $585.2 Mil.
Gross Profit was 44.933 + 55.124 + 43.701 + 33.473 = $177.2 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(871.059 + 868.666 + 854.834 + 856.53 + 835.51) / 5 = $857.3198 Mil.
Total Assets at the begining of this year (Dec22) was $871.1 Mil.
Long-Term Debt & Capital Lease Obligation was $409.0 Mil.
Total Current Assets was $190.7 Mil.
Total Current Liabilities was $109.5 Mil.
Net Income was -6.087 + -3.728 + -244.156 + -87.323 = $-341.3 Mil.

Revenue was 140.313 + 172.666 + 150.466 + 122.754 = $586.2 Mil.
Gross Profit was 44.726 + 50.936 + 42.225 + 25.49 = $163.4 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(1003.887 + 1139.421 + 1167.778 + 962.9 + 871.059) / 5 = $1029.009 Mil.
Total Assets at the begining of last year (Dec21) was $1,003.9 Mil.
Long-Term Debt & Capital Lease Obligation was $391.9 Mil.
Total Current Assets was $212.5 Mil.
Total Current Liabilities was $136.1 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Inotiv's current Net Income (TTM) was -33.2. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Inotiv's current Cash Flow from Operations (TTM) was 28.7. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-33.205/871.059
=-0.03812027

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-341.294/1003.887
=-0.33997253

Inotiv's return on assets of this year was -0.03812027. Inotiv's return on assets of last year was -0.33997253. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Inotiv's current Net Income (TTM) was -33.2. Inotiv's current Cash Flow from Operations (TTM) was 28.7. ==> 28.7 > -33.2 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=409.005/857.3198
=0.47707402

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=391.883/1029.009
=0.38083535

Inotiv's gearing of this year was 0.47707402. Inotiv's gearing of last year was 0.38083535. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=190.688/109.489
=1.74161788

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=212.528/136.127
=1.56124795

Inotiv's current ratio of this year was 1.74161788. Inotiv's current ratio of last year was 1.56124795. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Inotiv's number of shares in issue this year was 25.764. Inotiv's number of shares in issue last year was 25.603. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=177.231/585.172
=0.30286993

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=163.377/586.199
=0.2787057

Inotiv's gross margin of this year was 0.30286993. Inotiv's gross margin of last year was 0.2787057. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=585.172/871.059
=0.67179376

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=586.199/1003.887
=0.58392927

Inotiv's asset turnover of this year was 0.67179376. Inotiv's asset turnover of last year was 0.58392927. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+0+1+0+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Inotiv has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Inotiv  (NAS:NOTV) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Inotiv Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Inotiv's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Inotiv (Inotiv) Business Description

Traded in Other Exchanges
Address
2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Executives
John Gregory Beattie officer: Chief Operating Officer C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Michael Garrett officer: Chief Commercial Officer 250 PEHLE DRIVE, SUITE 601, SADDLE BROOK NJ 07663
Andrea Castetter officer: SVP, Gen. Counsel & Secretary 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
John E Sagartz director, officer: Chief Strategy Officer 19 WORTHINGTON ACCESS DRIVE, MARYLAND HEIGHTS MO 63043
David Landman director 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Robert Jr. Leasure director, officer: President and CEO C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Beth Taylor officer: Chief Financial Officer 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Jeffrey Arthur Krupp officer: Chief Human Resources Officer 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
William D Pitchford officer: Chief Human Resources Officer 1000 SAGAMORE PARKWAY SOUTH, LAFAYETTE IN 47905
R Matthew Neff director 535 N. COLLEGE DRIVE, CARMEL IN 46032
Jeffrey Brennan Freeman officer: VP-Finance & Corp. Controller 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Davis Gregory Cole director C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Nigel Brown director 250 PEHLE AVENUE, SUITE 600, SADDLE BROOK NJ 07663
Scott Cragg director 660 MADISON AVENUE, NEW YORK NY 10065

Inotiv (Inotiv) Headlines